The MarketWatch News Department was not involved in the creation of this content. TAIPEI, Aug. 28, 2025 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that the U.S.
Foresee Pharmaceuticals has shown that a long-acting version of its injectable prostate cancer med Camcevi can help patients with central precocious puberty (CPP), potentially opening the door to a ...
The independent Data and Safety Monitoring Board (DSMB) recommended the continuation of the study as planned. The Casppian study design included periodic evaluations and long-term safety monitoring ...
Metastatic prostate cancer is also referred to as stage 4 or advanced prostate cancer. It's cancer that began in the prostate, a gland located under the bladder of people assigned male at birth, and ...
TAIPEI, Aug. 28, 2025 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for ...